# Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

Source: https://onco.cc/trials/nct06926075/  
OnCo record `nct06926075` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of A novel hGIIA-Vimentin Inhibitor in prostate cancer, ovarian cancer, glioma & glioblastoma, pancreatic ductal adenocarcinoma and skin cancer, run by Filamon LTD, now recruiting.

## Summary

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours is a phase 1/2 interventional study registered as NCT06926075 by Filamon LTD, with 80 participants planned, started 2025-11-07 and due to reach its primary completion in 2027-10-26. Interventions recorded: A novel hGIIA-Vimentin Inhibitor and Dose expansion.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06926075
- Phase: 1/2
- Setting: An Adaptive Phase I/II Study of KESONOTIDE™, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours
- Sponsor: Filamon LTD
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06926075: https://clinicaltrials.gov/study/NCT06926075

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06926075.json